Product
the Recombinant SARS-COV-2 Fusion Protein Vaccine LIKANG V-01
In September 2022, the Recombinant SARS-COV-2 Fusion Protein Vaccine LIKANG V-01 developed by Livzon Mabpharm Inc. in collaboration with the Institute of Biophysics, Chinese Academy of Sciences, was proposed by the National Health Commission and approved by the National Medical Products Administration upon demonstration to be included for the emergency use as sequential booster immunization.
Classification
Key Words
LIVZON
- Product description
-
As the world's first vaccine to obtain clinical results of strong efficacy against Omicron, Likang V-01, with its "upgraded" recombinant protein immunogenicity and unique molecular design, is expected to overcome the main limitations and uncertainties of the first-generation SARS-CoV-2 vaccine and become a new generation of high-quality vaccine.
Related Products
online message
Note: Please leave your E-mail address and our professionals will contact you as soon as possible!